Optimalization of Nephroprotection Using Atorvastatin (Sortis)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of the study is find whether the addition of statin (Atorvastatin) to dual
renin-angiotensin-aldosterone system blockade involving angiotensin converting enzyme
inhibitor and AT-1 angiotensin II receptor blocker leads to the reduction of proteinuria,
main prognostic marker of chronic kidney disease progression.